List of Oligonucleotides Companies in South Korea - 3

Aptamer Sciences Inc. is a privately held biotech company focused on commercializing cutting-edge technologies for analysis of proteins, based on its proprietary aptamer technology platforms. Aptamer Sciences is dedicated to develop the aptamer technologies to generate high quality aptamer and in broad applications of research, diagnosis and therapeutics. Compared to conventional aptamer generating technologies, Aptamer Sciences has developed advanced aptamer technologies and thus can generate aptamers more efficiently with superior binding affinity. Aptamer Sciences has ongoing collaboration relationships with several industry partners. The Company also has research collaboration with several universities, hospitals and research organizations. Aptamer Sciences was founded in 2011 by researchers from POSTECH BIOTECH CENTER and is based in Pohang, South Korea. Aptamer Sciences is currently funded by aptamer service revenue and grants, as well as by investments from strategic investors.

OliX Pharmaceuticals is a clinical stage pharmaceutical company developing therapeutics based on the science of RNAi to address a wide variety of illnesses. The Company has developed core platforms (asymmetric siRNA, cell-penetrating asiRNA) targeting locally administrable diseases, such as hypertrophic scars, hair loss, and age-related macular degeneration (AMD). OliX's third RNAi therapeutic platform, GalNAc-asiRNA, targets multiple liver diseases, including NASH/diabetes and HBV. For the general welfare of human beings, OliX is constantly endeavoring to become a leader in the global biotechnology industry by innovating and expanding its pipeline, even to the undruggable diseases.

"ST Pharm provides reliable and timely custom manufacturing services for API following stringent quality system and close communication with the clients." Founded in 1983, ST Pharm (formerly known as Samchully Pharmaceutical) has been offering excellent custom manufacturing services of APIs and their intermediates to meet clients' high expectation for their use in pharmaceutical development in compliant to cGMP requirements. Our reliability in service, which is well-proven through decades of business relationship with many big pharmas and biotech clients, is the essence of our strength along with our expertise in process development and scale-up optimization. Historically, ST Pharm has been focusing our expertise on nucleoside based active pharmaceuticals in various antiviral drug applications; we became the world largest supplier of Thymidine in the late 1990s and Zidovudine in the mid 2000s and protected nucleosides in the early 2000s. ST Pharm has continuously been expanding its service offering, including synthesis of therapeutic oligonucleotides. In June 2010, ST Pharm became a subsidiary of Dong-A Pharmaceutical, the top pharmaceutical company in Korea. ST Pharm is committed to expanding its business scope into generic APIs and their intermediates with full support and collaboration with parent company Dong-A Pharmaceutical.